Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses

BERWYN, Pa., February 1, 2023 /PRNewswire/ — Annovis Bio, Inc . (NYSE: ANVS) (“Annovis” or the “Company”), a company with a clinical-stage drug platform addressing Alzheimer’s and Parkinson’s disease, today announced a patent filing that expands the breadth of its platform from neurodegenerative to neuropsychiatric indications: ” Treatment of Mental Illness through the Administration of Buntanetap and Analogues.”

Annovis (PRNewsfoto/Annovis Bio)

Five major mental illnesses—autism, attention deficit hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia—appear to share some common features: dysregulation of Abeta and other neurotoxic protein synthesis similar to neurodegenerative diseases.1dysfunctional nerve cell transmission and communication and genetic risk factors by examining genetic data from more than 60,000 people worldwide2.

For the purposes of this patent application, these common features are presented to show that many of these disorders show abnormal patterns of neurotoxic aggregated proteins in the brain, have abnormal axonal transport and synaptic transmission problems, and have partial overlap in etiology, including but not limited to a genetic component.

In certain embodiments, the invention encompasses methods and pharmaceutical compositions of a large group of buntanetap analogs for preventing, treating, inhibiting, reducing, slowing or delaying mental illness in humans. In certain embodiments, the mental illness is autism, attention deficit hyperactivity disorder, bipolar disorder, major depressive disorder, or schizophrenia.

“Mental diseases show abnormal levels of neurotoxic proteins. These neurotoxic proteins cause damage to axonal transmission and inflammation, similar to what is seen in neurodegenerative diseases. In fact, axonal transport and synaptic transmission are severely affected in neuropsychiatric disorders, and our drug restores axonal transport and synaptic transmission,” said Maria L. Macekini, Ph.D., Founder, President and CEO of Anovis. “In phase 2a trials in Alzheimer’s disease and Parkinson’s disease, treatment with buntanetap resulted in improved axonal and synaptic function, as well as cognitive and functional health. “Through its unique ability to inhibit a range of aggregated proteins, we believe buntanetap has the potential to restore protein homeostasis and delay the progression of a number of mental illnesses.”

Also Read :  ‘Spider-Man’ Star Laura Harrier Is a ‘Big Advocate’ for Therapy for Black Communities – SheKnows

Summary of key coverage:

  • A method of preventing, treating, inhibiting, reducing, slowing or delaying the onset of a mental illness such as autism, attention deficit hyperactivity disorder (ADHD), bipolar disorder, major depressive disorder or schizophrenia.
  • The agent administered will be buntanetap or its analogues used alone or in combination with an antipsychotic, antidepressant or hallucinogenic agent.

The company has issued patents covering a wide range of neurodegenerative diseases, and this patent, if approved, would represent a significant expansion of Anovis’ intellectual property portfolio. Current patents cover neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal dementia (FTD), chronic traumatic encephalopathy (CTE), acute injuries such as stroke and traumatic brain injury, amyloid lateral sclerosis ( ALS), Huntington’s disease and prion diseases.

1Mental illness and amyloid, Brain Sci. 2021, vol. 11, number 1352, P1-14

2Identification of risk loci with common effects on five major psychiatric disorders: a genome-wide analysis, The Lancet, Vol. 381, Issue 9875, P1371-1379, published online February 28, 2013

About Buntanetap
Buntanetap (previously known as ANVS401 or Posiphen) is an oral translational inhibitor of neurotoxic aggregated proteins (TINAPs) that play a role in axonal injury, inflammation and cell death. By targeting these mechanisms, buntanetap has been shown to improve cognitive function in patients with various neurodegenerative disorders. In a Phase 2a clinical trial in AD and PD patients, buntanetap was well tolerated and safe and resulted in a statistically significant improvement in motor function in PD patients and cognition in AD patients.

About Annovis Bio, Inc.
Based in Berwyn, Pennsylvania, Annovis Bio, Inc. is a clinical-stage, drug platform company developing transformative therapies that treat neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and other chronic and acute neurodegenerative diseases. The company believes it is the only company developing a drug that inhibits more than one neurotoxic protein, improves the nerve cell’s information highway, known as axonal transport, reduces inflammation and protects nerve cells from death in chronic and acute neurodegeneration. Anovis conducted two Phase 2 studies: one in patients with AD and one in patients with both AD and PD. In the AD/PD study, buntanetap showed improvements in cognition and memory in AD, as well as body and brain function in PD patients.

For more information about Annovis Bio, visit the company’s website at and follow us on LinkedIn and Twitter.

Forward-looking statements
The statements in this press release contain “forward-looking statements” that are subject to significant risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project” , “Forecast,” “forecast” or other similar words and includes, without limitation, statements regarding the timing, effectiveness and expected results of Buntanetap clinical trials. Forward-looking statements are based on Annovis Bio, Inc.’s current expectations. and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Furthermore, certain forward-looking statements are based on assumptions about future events that may not be accurate. These and other risks and uncertainties are more fully described in the section entitled “Risk Factors” in the Annual Report on Form 10-K for the year then ended. December 31, 2021, filed with the Securities and Exchange Commission. The forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no obligation to update such information except as required by applicable law.

Media contact

Nick Johnson
Russo Partners, LLC
(303) 482-6405
[email protected]

Contact with investors:

Chris Calabrese
+1 (917) 680-5608
[email protected]
LifeSci Advisors, LLC

Kevin Gardner

+1 (617) 283-2856
[email protected]
LifeSci Advisors, LLC

Cision View original content for multimedia download: for -treatment-mental-illness-301735683.html

SOURCE Annovis Bio


Also Read :  Lost and Found in Crown Heights: The Soul House

Leave a Reply

Your email address will not be published.